Literature DB >> 20390120

[Antiphospholipid antibody: laboratory, pathogenesis and clinical manifestations].

A Tincani1, C Casu, S Cartella, T Ziglioli, R Cattaneo.   

Abstract

Antiphospholipid antibodies (aPL) represent a heterogeneous group of antibodies that recognize various antigenic targets including beta2 glycoprotein I (beta2GPI), prothrombin (PT), activated protein C, tissue plasminogen activator, plasmin and annexin A2. The most commonly used tests to detect aPL are: lupus anticoagulant (LAC), a functional coagulation assay, anticardiolipin antibody (aCL) and anti-beta2GPI antibody (anti-beta2GPI), which are enzyme-linked immunoassay (ELISA). Clinically aPL are associated with thrombosis and/or with pregnancy morbidity. Apparently aPL alone are unable to induce thrombotic manifestations, but they increase the risk of vascular events that can occur in the presence of another thrombophilic condition; on the other hand obstetrical manifestations were shown to be associated not only to thrombosis but mainly to a direct antibody effect on the trophoblast.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20390120     DOI: 10.4081/reumatismo.2010.65

Source DB:  PubMed          Journal:  Reumatismo        ISSN: 0048-7449


  3 in total

1.  M pneumoniae infection, pulmonary thromboembolism and antiphospholipid antibodies.

Authors:  Elia Ascer; Marcus Marques; Magnus Gidlund
Journal:  BMJ Case Rep       Date:  2011-04-19

2.  A large and massive abdominal venous thrombosis associated with the presence of a big axillary mass, lupus-like syndrome and antiphospholipid antibodies.

Authors:  Elia Ascer; Liv Goldstein Ascer; Magnus Gidlund
Journal:  BMJ Case Rep       Date:  2011-06-29

3.  Antiphospholipid Syndrome - A Case Report of Pulmonary Thromboembolism, Followed with Acute Myocardial Infarction in Patient with Systemic Sclerosis.

Authors:  Marija Vavlukis; Irina Kotlar; Emilija Chaparoska; Bekim Pocesta; Hristo Pejkov; Marjan Boshev; Sasko Kedev
Journal:  Open Access Maced J Med Sci       Date:  2015-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.